PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial

Phase 2positiverezatapoptPositive

AI Analysis

Summary

PMV Pharmaceuticals announced updated interim ovarian cancer data from the PYNNACLE Phase 2 pivotal trial of rezatapopt monotherapy in patients with TP53 Y220C advanced solid tumors at 2000 mg once-daily dosing.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Updated interim ovarian cancer data announced from PYNNACLE Phase 2 pivotal trial

Importance:6/10

Sentiment:

0.70

oncologyp53precision medicineovarian cancermonotherapyPhase 2 data

Related Companies

$PMVP

Read the original article

Published by GlobeNewswire Pharma on August 31, 2026 8:01 PM

Read Original